...
首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70Gy daily radiotherapy: CALGB 30904
【24h】

Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70Gy daily radiotherapy: CALGB 30904

机译:诱导化疗后同时进行铂类化疗和每日70Gy放疗的有限期小细胞肺癌患者的肺毒性预测因子:CALGB 30904

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Standard therapy for limited stage small cell lung cancer (L-SCLC) is concurrent chemotherapy and radiotherapy followed by prophylactic cranial radiotherapy. Predictors of post chemoradiotherapy pulmonary toxicity in limited stage (LS) small cell lung cancer (SCLC) patients are not well defined. Current guidelines are derived from non-small cell lung cancer regimens, and do not account for the unique biology of this disease. Therefore, we analyzed patients on three consecutive CALGB LS-SCLC trials treated with concurrent chemotherapy and daily high dose radiotherapy (70. Gy) to determine patient and treatment related factors predicting for post-treatment pulmonary toxicity. Methods: Patients treated on CALGB protocols 39808, 30002, 30206 investigating two cycles of chemotherapy followed by concurrent chemotherapy and 70. Gy daily thoracic radiation therapy were pooled. Patient, tumor, and treatment related factors were evaluated to determine predictors of grade 3-5 pulmonary toxicities after concurrent chemoradiotherapy. Results: 100 patients were included. No patient experienced grade 4-5 post-treatment pulmonary toxicity. Patients who experienced post-treatment pulmonary toxicity were more likely to be older (median age 69 vs 60, p= 0.09) and have smaller total lung volumes (2565 cc vs 3530 cc, p= 0.05).). Furthermore, exposure of larger volumes of lung to lower (median V5. = 70%, p= 0.09, median V10. = 63%, p= 0.07), intermediate (median V20. = 50, p= 0.04) and high (median V60. = 25%, p= 0.01) doses of radiation were all associated with post-treatment grade 3 pulmonary toxicity, as was a larger mean lung radiation dose (median 31. Gy) p= 0.019. Conclusion: Post-treatment pulmonary toxicity following the completion of 2 cycles of chemotherapy followed by concurrent chemotherapy and high dose daily radiation therapy was uncommon. Care should be taken to minimize mean lung radiation exposure, as well as volumes of low, intermediate and high doses of radiation.
机译:简介:有限期小细胞肺癌(L-SCLC)的标准疗法是同步化疗和放疗,然后进行预防性颅脑放疗。局限期(LS)小细胞肺癌(SCLC)患者的放化疗后肺毒性的预测因素尚不明确。当前的指南源自非小细胞肺癌治疗方案,并不能说明该疾病的独特生物学特性。因此,我们通过连续化疗和每日高剂量放疗(70. Gy)连续进行的CALGB LS-SCLC三项连续试验对患者进行分析,以确定预测治疗后肺毒性的患者和治疗相关因素。方法:按照CALGB协议39808、30002、30206治疗的患者,研究了两个化疗周期,然后同时进行化疗和70。每天合并Gy胸腔放疗。评估患者,肿瘤和治疗相关因素,以确定同时放化疗后3-5级肺毒性的预测因子。结果:包括100例患者。没有患者经历过治疗后的4-5级肺毒性。经历过治疗后肺毒性的患者更有可能年龄更大(中位年龄为69岁vs 60岁,p = 0.09),总肺容量较小(2565 cc vs 3530 cc,p = 0.05)。此外,较大量的肺暴露于较低(中位数V5。= 70%,p = 0.09,中位数V10。= 63%,p = 0.07),中度(中位数V20。= 50,p = 0.04)和较高(中位数) V60。= 25%,p = 0.01)剂量的放射线均与治疗后3级肺毒性有关,较大的平均肺部放射剂量(中位数31. Gy)p = 0.019。结论:在完成2个周期的化疗后再进行同步化疗和每日大剂量放疗后,治疗后的肺毒性并不常见。应注意尽量减少平均肺部辐射以及低,中和高剂量的辐射量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号